文献速递临床试验与 GCP流行病学与生物统计

饮用含咖啡因咖啡或戒断咖啡因以减少心房颤动:DECAF随机临床试验

Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项前瞻性开放标签随机临床试验纳入200名计划接受电复律的持续性心房颤动或心房扑动成人,1:1随机分为6个月内每日至少饮用1杯含咖啡因咖啡组与完全戒断咖啡因组。主要终点为6个月内临床检测到的心房颤动或心房扑动复发。咖啡组复发率47%,戒断组64%,风险比0.61(95%CI 0.42-0.89;P=0.01),不良事件无显著差异。

要点

  • 在计划电复律的房颤或房扑患者中,饮用含咖啡因咖啡组6个月复发率47%,戒断组64%。
  • 咖啡组较戒断组复发风险降低39%(HR 0.61,95%CI 0.42-0.89;P=0.01)。
  • 仅分析房颤复发时观察到与主要终点一致的获益,不良事件无显著差异。

核心结论

  • 在成功电复律后的习惯饮用咖啡人群中,分配至平均每日约1杯含咖啡因咖啡与戒断咖啡及含咖啡因产品相比,与更少的心房颤动或心房扑动复发相关。

研究设计与样本

  • 前瞻性、开放标签、随机临床试验,于2021年11月至2024年12月在美国、加拿大和澳大利亚的5家医院纳入200名当前或过去5年内饮用咖啡、患有持续性心房颤动或伴有心房颤动史的心房扑动、计划接受电复律的成人。
  • 患者按1:1比例随机分配至规律饮用含咖啡因咖啡组(n=100)或戒断咖啡及咖啡因组(n=100),干预持续6个月;咖啡组鼓励每日至少饮用1杯含咖啡因咖啡,戒断组鼓励完全戒断含咖啡因和脱咖啡因咖啡及其他含咖啡因产品。
  • 最终随访日期为2025年6月5日;主要终点为6个月内临床检测到的心房颤动或心房扑动复发。

主要发现

  • 200名患者平均(SD)年龄69(11)岁,71%为男性;两组基线咖啡摄入量均为每周7杯(IQR 7-18)。
  • 随访期间咖啡组咖啡摄入量为每周7杯(IQR 6-11),戒断组为每周0杯(IQR 0-2),组间差异为每周7杯(95%CI 7-7)。
  • 主要分析中,咖啡组心房颤动或心房扑动复发率为47%,戒断组为64%,复发风险降低39%(HR 0.61,95%CI 0.42-0.89;P=0.01)。
  • 仅分析心房颤动复发时观察到与主要终点一致的咖啡饮用获益。
  • 不良事件无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Conventional wisdom holds that caffeinated coffee is proarrhythmic. Coffee is the most commonly consumed caffeinated beverage in the US, and a randomized trial assessing caffeinated coffee consumption in patients with atrial fibrillation (AF) has not previously been performed. OBJECTIVE: To determine the effect of caffeinated coffee consumption compared with abstinence from coffee and caffeine on recurrent AF. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, open-label, randomized clinical trial enrolling 200 current or previous (within past 5 years) coffee-drinking adults with persistent AF, or atrial flutter with a history of AF, planned for electrical cardioversion from 5 hospitals in the US, Canada, and Australia between November 2021 and December 2024. The date of final follow-up was June 5, 2025. INTERVENTION: Patients were randomized in a 1:1 ratio to regular caffeinated coffee consumption vs coffee and caffeine abstinence for 6 months. Patients in the coffee consumption group were encouraged to drink at least 1 cup of caffeinated coffee daily. Patients in the abstinence group were encouraged to completely abstain from both caffeinated and decaffeinated coffee and other caffeine-containing products. MAIN OUTCOMES AND MEASURES: The primary end point was clinically detected recurrence of AF or atrial flutter over 6 months. RESULTS: Two hundred patients (mean [SD] age, 69 [11] years; 71% male) were randomized to caffeinated coffee consumption (n = 100) or coffee abstinence (n = 100). Baseline coffee intake was 7 cups (IQR, 7-18) per week in both groups. During follow-up, coffee intake in the consumption and abstinence groups was 7 (IQR, 6-11) and 0 (IQR, 0-2) cups per week, respectively, resulting in a between-group difference of 7 cups (95% CI, 7-7) per week. In the primary analysis, AF or atrial flutter recurrence was less in the coffee consumption (47%) than the coffee abstinence (64%) group, resulting in a 39% lower hazard of recurrence (hazard ratio, 0.61 [95% CI, 0.42-0.89]; P = .01). A comparable benefit of coffee consumption was observed with AF recurrence only. There was no significant difference in adverse events. CONCLUSIONS AND RELEVANCE: In this clinical trial of coffee drinkers after successful cardioversion, allocation to consumption of caffeinated coffee averaging 1 cup a day was associated with less recurrence of AF or atrial flutter compared with abstinence from coffee and caffeinated products. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05121519.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Wong CX, Cheung CC, Montenegro G, et al. Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial. JAMA. 2026. PMID: 41206802. doi:10.1001/jama.2025.21056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。